| Drug General Information |
| Drug ID |
D06EXH
|
| Former ID |
DNC011984
|
| Drug Name |
(4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C7H14N2O
|
| Canonical SMILES |
CCC1C(OC(=N1)N)CC
|
| InChI |
1S/C7H14N2O/c1-3-5-6(4-2)10-7(8)9-5/h5-6H,3-4H2,1-2H3,(H2,8,9)/t5-,6-/m0/s1
|
| InChIKey |
KYKDCIRQVPPSOP-WDSKDSINSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Nitric-oxide synthase, brain |
Target Info |
Inhibitor |
[1]
|
|---|
| Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
Phagosome
|
|
Circadian entrainment
|
|
Long-term depression
|
|
Salivary secretion
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)hsa00220:Arginine biosynthesis
|
|
HIF-1 signaling pathway
|
|
Peroxisome
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Pathways in cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
EGFR1 Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
IL12-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
ATF-2 transcription factor network
|
|
IL23-mediated signaling events
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
HIF-1-alpha transcription factor network
|
|
PathWhiz Pathway
|
Arginine and Proline Metabolism
|
|
Reactome
|
ROS production in response to bacteria
|
|
Nitric oxide stimulates guanylate cyclaseR-HSA-1222556:ROS production in response to bacteria
|
|
Nitric oxide stimulates guanylate cyclase
|
|
WikiPathways
|
Monoamine Transport
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Spinal Cord Injury
|
|
Alzheimers Disease
|
|
Effects of Nitric Oxide
|
|
Serotonin Transporter ActivityWP619:Type II interferon signaling (IFNG)
|
|
AGE/RAGE pathway
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. |
|---|
